Enliven Therapeutics Inc (ELVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2017 | 12-2006 | 12-2005 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -41,360 | -23,463 | N/A | N/A | N/A |
| Depreciation Amortization | 219 | 14 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 313 | 750 | N/A | N/A | N/A |
| Other Working Capital | 1,512 | 673 | N/A | N/A | N/A |
| Other Operating Activity | 1,918 | 149 | 0 | 0 | 0 |
| Operating Cash Flow | $-37,398 | $-21,877 | $N/A | $N/A | $N/A |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -16,703 | -23,920 | N/A | N/A | N/A |
| PPE Investments | -18 | -140 | N/A | N/A | N/A |
| Investing Cash Flow | $-16,721 | $-24,060 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 81,449 | N/A | N/A | N/A | N/A |
| Other Financing Activity | 15,432 | 43,579 | 0 | 0 | 0 |
| Financing Cash Flow | $96,881 | $43,579 | $N/A | $N/A | $N/A |
| Beginning Cash Position | 5,024 | 7,382 | N/A | N/A | N/A |
| End Cash Position | 47,786 | 5,024 | N/A | N/A | N/A |
| Net Cash Flow | $42,762 | $-2,358 | $N/A | $N/A | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -37,398 | -21,877 | N/A | N/A | N/A |
| Capital Expenditure | -18 | -140 | N/A | N/A | N/A |
| Free Cash Flow | -37,416 | -22,017 | 0 | 0 | 0 |